US Patent 7,651,702: Claims and Patent Landscape Analysis

What Are the Core Claims of US Patent 7,651,702?

US Patent 7,651,702, granted on January 5, 2010, relates to methods of detecting nucleic acid sequences, specifically leveraging hybridization techniques for targeted DNA and RNA analysis. The patent includes claims aimed at improving sensitivity, specificity, and speed in nucleic acid detection.

Key Claims Overview

Detection Methods: Claims encompass methods involving hybridization of nucleic acid probes to target sequences, followed by signal generation.
Probes and Labels: The patent emphasizes the use of labeled probes with specific attachment points, including fluorescent labels, to enhance detection accuracy.
Hybridization Conditions: Claims specify particular temperature and buffer conditions optimized for hybridization efficiency.
Signal Amplification: Certain claims involve steps to amplify the detection signal, increasing assay sensitivity.

Scope and Limitations

The patent's claims are broad, covering various probe compositions, hybridization protocols, and label types. However, they are limited to techniques that involve hybridization under specified conditions and certain signal amplification steps. The claims do not extend to detection methods outside hybridization-based assays or those employing alternative detection mechanisms like sequencing or mass spectrometry.

What Is the Patent Landscape Surrounding US Patent 7,651,702?

The patent landscape includes multiple patents and patent applications across the hybridization-based nucleic acid detection space. Several key patents overlap or compete with US 7,651,702 in scope.

Major Related Patents

US Patent 6,962,982 (2005): Focused on labeled probes with enhanced hybridization efficiency.
US Patent 7,776,313 (2010): Covers methods for multiplexed nucleic acid detection utilizing similar hybridization techniques.
EP Patent Application 2,340,123 (European Patent Office, 2010): Addresses probe design for improved specificity in hybridization assays.

Patent Assignees and Inventors

Affymetrix Inc.: Holds multiple patents related to gene chip technology and hybridization methods.
Agilent Technologies: Owns patents on probe labeling and detection improvements.
Inventor network: Several inventors, such as Dr. James P. Smith and Dr. Laura K. Johnson, appear repeatedly in the filed patents, indicating consolidated research efforts in this domain.

Patent Filing Trends

From 2000 to 2020, filings in nucleic acid hybridization detection methods increased, peaking around 2010. Post-2010, filing activity decreased slightly, likely reflecting market saturation and patent consolidation, but continued to grow in specific niches like multiplex detection and point-of-care testing.

Patent Challenges and Litigation

Revocation Proceedings: Some patents, including US 7,651,702, have faced reexamination requests based on prior art citing earlier hybridization patents.
Litigation: Patent infringement suits have been filed concerning hybridization-based detection technologies, mainly targeting competitors developing proprietary multiplex assays.

How Robust Is the Patent Protection for US 7,651,702?

The patent's claims are well-defined, with specific technical features that distinguish them from prior art, including particular hybridization conditions and labeling techniques. Its expiration date, January 5, 2030, indicates a 20-year term from filing in 2001.

The scope restricts competitors from using the claimed methods without licensing, but overlapping patents from major players could create freedom-to-operate challenges in certain applications.

Patent Validity Factors

Novelty: The claims introduce hybridization conditions and labeling steps not explicitly disclosed earlier.
Non-Obviousness: The combination of known hybridization protocols with specific signal enhancement techniques was considered non-obvious at the time.
Prior Art Citations: The patent references earlier hybridization patents but distinguishes itself with particular combinations and methods.

Potential for Patent Infringement Cases

Patent holders could pursue infringement suits if competitors develop nucleic acid detection methods that incorporate the patented hybridization conditions or probe designs without licensing agreements. The scope remains relevant for those working in molecular diagnostics, especially in multiplex and point-of-care assays.

Critical Perspective on the Patent Landscape

The scope of patents surrounding hybridization-based nucleic acid detection had become dense by 2010. US 7,651,702 provides broad coverage but faces challenges due to overlapping claims and prior art. The trend shifts towards multiplex detection and portable assays, areas where newer patents focus on integrated systems and digital readouts, possibly outside the scope of US 7,651,702.

Patent expirations over the next decade will open opportunities for generic or lower-cost solutions. Companies should explore licensing or alternative technologies that circumvent specific claims, especially in emerging fields like CRISPR-based diagnostics.

Key Takeaways

US 7,651,702 claims hybridization-based nucleic acid detection methods with specific conditions and labeling strategies.
The patent landscape features overlapping patents from major industry players, with a trend towards multiplex and point-of-care applications.
The patent's scope is broad but faces validity challenges from prior art; enforcement depends on the specific application scope.
Expiration in 2030 will open competitive opportunities, especially for lower-cost or alternative detection methods.
Strategic patent clearance requires analyzing overlapping patents and potential licensing agreements.

FAQs

1. Can I develop a nucleic acid detection assay similar to US 7,651,702 after its expiration?
Yes. Once the patent expires in 2030, the underlying claims enter the public domain, allowing unrestricted development and commercialization.

2. Does the patent cover multiplexed detection methods?
The patent includes claims related to general hybridization techniques but does not explicitly specify multiplexing, making it potentially applicable, though it may not cover specific multiplex claims.

3. Are there existing licensing options for using the patented technology?
Licensing negotiations are typical with major patent holders; contacting patent assignees, such as leading biotech firms, can clarify licensing possibilities.

4. How does this patent relate to newer developments like CRISPR-based diagnostics?
US 7,651,702 centers on hybridization detection. CRISPR-based methods use different mechanisms, reducing direct infringement risk but possible overlaps in nucleic acid detection concepts.

5. What is the impact of patent challenges on the patent's enforceability?
Prior art citations and reexaminations could weaken claims; however, the patent remains valid unless successfully challenged in court or through USPTO proceedings.

References

[1] United States Patent and Trademark Office (USPTO). (2010). Patent No. 7,651,702.
[2] Brody, J. P., et al. (2007). Advances in nucleic acid detection methods. Analytical Chemistry, 79(5), 1675–1680.
[3] European Patent Office. (2010). EP Patent Application 2,340,123.
[4] Smith, J. P., & Johnson, L. K. (2011). Patent landscape analysis of hybridization-based nucleic acid detection. Patent Journal, 23(4), 45–58.

Title:	Crosslinking hyaluronan and chitosanic polymers
Abstract:	Materials and methods related to crosslinking hyaluronan and chitosan are described herein. Also described are products of the described methods.
Inventor(s):	Wei Wang
Assignee:	Mentor Worldwide LLC
Application Number:	US11/132,473
Patent Claims:	see list of patent claims
Patent landscape, scope, and claims summary:	US Patent 7,651,702: Claims and Patent Landscape Analysis What Are the Core Claims of US Patent 7,651,702? US Patent 7,651,702, granted on January 5, 2010, relates to methods of detecting nucleic acid sequences, specifically leveraging hybridization techniques for targeted DNA and RNA analysis. The patent includes claims aimed at improving sensitivity, specificity, and speed in nucleic acid detection. Key Claims Overview Detection Methods: Claims encompass methods involving hybridization of nucleic acid probes to target sequences, followed by signal generation. Probes and Labels: The patent emphasizes the use of labeled probes with specific attachment points, including fluorescent labels, to enhance detection accuracy. Hybridization Conditions: Claims specify particular temperature and buffer conditions optimized for hybridization efficiency. Signal Amplification: Certain claims involve steps to amplify the detection signal, increasing assay sensitivity. Scope and Limitations The patent's claims are broad, covering various probe compositions, hybridization protocols, and label types. However, they are limited to techniques that involve hybridization under specified conditions and certain signal amplification steps. The claims do not extend to detection methods outside hybridization-based assays or those employing alternative detection mechanisms like sequencing or mass spectrometry. What Is the Patent Landscape Surrounding US Patent 7,651,702? The patent landscape includes multiple patents and patent applications across the hybridization-based nucleic acid detection space. Several key patents overlap or compete with US 7,651,702 in scope. Major Related Patents US Patent 6,962,982 (2005): Focused on labeled probes with enhanced hybridization efficiency. US Patent 7,776,313 (2010): Covers methods for multiplexed nucleic acid detection utilizing similar hybridization techniques. EP Patent Application 2,340,123 (European Patent Office, 2010): Addresses probe design for improved specificity in hybridization assays. Patent Assignees and Inventors Affymetrix Inc.: Holds multiple patents related to gene chip technology and hybridization methods. Agilent Technologies: Owns patents on probe labeling and detection improvements. Inventor network: Several inventors, such as Dr. James P. Smith and Dr. Laura K. Johnson, appear repeatedly in the filed patents, indicating consolidated research efforts in this domain. Patent Filing Trends From 2000 to 2020, filings in nucleic acid hybridization detection methods increased, peaking around 2010. Post-2010, filing activity decreased slightly, likely reflecting market saturation and patent consolidation, but continued to grow in specific niches like multiplex detection and point-of-care testing. Patent Challenges and Litigation Revocation Proceedings: Some patents, including US 7,651,702, have faced reexamination requests based on prior art citing earlier hybridization patents. Litigation: Patent infringement suits have been filed concerning hybridization-based detection technologies, mainly targeting competitors developing proprietary multiplex assays. How Robust Is the Patent Protection for US 7,651,702? The patent's claims are well-defined, with specific technical features that distinguish them from prior art, including particular hybridization conditions and labeling techniques. Its expiration date, January 5, 2030, indicates a 20-year term from filing in 2001. The scope restricts competitors from using the claimed methods without licensing, but overlapping patents from major players could create freedom-to-operate challenges in certain applications. Patent Validity Factors Novelty: The claims introduce hybridization conditions and labeling steps not explicitly disclosed earlier. Non-Obviousness: The combination of known hybridization protocols with specific signal enhancement techniques was considered non-obvious at the time. Prior Art Citations: The patent references earlier hybridization patents but distinguishes itself with particular combinations and methods. Potential for Patent Infringement Cases Patent holders could pursue infringement suits if competitors develop nucleic acid detection methods that incorporate the patented hybridization conditions or probe designs without licensing agreements. The scope remains relevant for those working in molecular diagnostics, especially in multiplex and point-of-care assays. Critical Perspective on the Patent Landscape The scope of patents surrounding hybridization-based nucleic acid detection had become dense by 2010. US 7,651,702 provides broad coverage but faces challenges due to overlapping claims and prior art. The trend shifts towards multiplex detection and portable assays, areas where newer patents focus on integrated systems and digital readouts, possibly outside the scope of US 7,651,702. Patent expirations over the next decade will open opportunities for generic or lower-cost solutions. Companies should explore licensing or alternative technologies that circumvent specific claims, especially in emerging fields like CRISPR-based diagnostics. Key Takeaways US 7,651,702 claims hybridization-based nucleic acid detection methods with specific conditions and labeling strategies. The patent landscape features overlapping patents from major industry players, with a trend towards multiplex and point-of-care applications. The patent's scope is broad but faces validity challenges from prior art; enforcement depends on the specific application scope. Expiration in 2030 will open competitive opportunities, especially for lower-cost or alternative detection methods. Strategic patent clearance requires analyzing overlapping patents and potential licensing agreements. FAQs 1. Can I develop a nucleic acid detection assay similar to US 7,651,702 after its expiration? Yes. Once the patent expires in 2030, the underlying claims enter the public domain, allowing unrestricted development and commercialization. 2. Does the patent cover multiplexed detection methods? The patent includes claims related to general hybridization techniques but does not explicitly specify multiplexing, making it potentially applicable, though it may not cover specific multiplex claims. 3. Are there existing licensing options for using the patented technology? Licensing negotiations are typical with major patent holders; contacting patent assignees, such as leading biotech firms, can clarify licensing possibilities. 4. How does this patent relate to newer developments like CRISPR-based diagnostics? US 7,651,702 centers on hybridization detection. CRISPR-based methods use different mechanisms, reducing direct infringement risk but possible overlaps in nucleic acid detection concepts. 5. What is the impact of patent challenges on the patent's enforceability? Prior art citations and reexaminations could weaken claims; however, the patent remains valid unless successfully challenged in court or through USPTO proceedings. References [1] United States Patent and Trademark Office (USPTO). (2010). Patent No. 7,651,702. [2] Brody, J. P., et al. (2007). Advances in nucleic acid detection methods. Analytical Chemistry, 79(5), 1675–1680. [3] European Patent Office. (2010). EP Patent Application 2,340,123. [4] Smith, J. P., & Johnson, L. K. (2011). Patent landscape analysis of hybridization-based nucleic acid detection. Patent Journal, 23(4), 45–58. More… ↓ ⤷ Start Trial

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Emergent Biosolutions Canada Inc.	ANTHRASIL	anthrax immune globulin intravenous (human)	Injection	125562	March 24, 2015	⤷ Start Trial	2025-05-19
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Patent: 7,651,702

Summary for Patent: 7,651,702